Resultats de la cerca - Michael Untch

Refinar resultats
  1. 1
    Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up

    Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up per Nadia Harbeck, Michael Untch, L. Pache, W. Eiermann

    Publicat 1994
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Breast Reconstruction Following Cancer Treatment

    Breast Reconstruction Following Cancer Treatment per Bernd Gerber, Mario Marx, Michael Untch, Andreé Faridi

    Publicat 2015
    Obtenir text complet
    Errata/Corrigenda
    Afegir a favorits
    Guardat en:
  3. 3
    Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer

    Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer per Hope S. Rugo, Giampaolo Bianchini, Javier Cortés, Jan‐Willem Henning, Michael Untch

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Contextual factors in shared decision making: a randomised controlled trial in women with a strong suspicion of breast cancer

    Contextual factors in shared decision making: a randomised controlled trial in women with a strong suspicion of breast cancer per Andrea Vodermaier, Cornelia Caspari, Janna Koehm, Steffen Kahlert, Nina Ditsch, Michael Untch

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Phyllodes tumour of the breast: Clinical follow-up of 33 cases of this rare disease

    Phyllodes tumour of the breast: Clinical follow-up of 33 cases of this rare disease per Miriam Lenhard, Steffen Kahlert, Isabelle Himsl, Nina Ditsch, Michael Untch, Ingo Bauerfeind

    Publicat 2007
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Current and future role of neoadjuvant therapy for breast cancer

    Current and future role of neoadjuvant therapy for breast cancer per Michael Untch, Gottfried E. Konecny, Stefan Paepke, Gϋnter von Minckwitz

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Short‐term effects of treatment‐induced hormonal changes on cognitive function in breast cancer patients

    Short‐term effects of treatment‐induced hormonal changes on cognitive function in breast cancer patients per Kerstin Hermelink, Volkmar Henschel, Michael Untch, Ingo Bauerfeind, Michael P. Lux, Karin Münzel

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Cognitive function during neoadjuvant chemotherapy for breast cancer

    Cognitive function during neoadjuvant chemotherapy for breast cancer per Kerstin Hermelink, Michael Untch, Michael P. Lux, R. Kreienberg, Thomas Beck, Ingo Bauerfeind, Karin Münzel

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Nucleosomes in Serum as a Marker for Cell Death

    Nucleosomes in Serum as a Marker for Cell Death per Stefan Holdenrieder, P Stieber, Heinz Bodenmüller, Georg Fertig, Heinrich Fürst, N. Schmeller, Michael Untch, D. Seidel

    Publicat 2001
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance

    A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance per Thorsten Kuehn, A. Bembenek, Thomas Decker, D. L. Munz, Marie‐Luise Sautter‐Bihl, Michael Untch, D. Wallwiener

    Publicat 2004
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  11. 11
    Serum CEA and CA 15-3 as prognostic factors in primary breast cancer

    Serum CEA and CA 15-3 as prognostic factors in primary breast cancer per F G Ebeling, P Stieber, Michael Untch, D. Nagel, Gottfried E. Konecny, Urban Schmitt, A. Fateh‐Moghadam, D. Seidel

    Publicat 2002
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer

    The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer per Oumar Camara, Matthias Rengsberger, A Egbe, André Koch, Mieczysław Gajda, Ulrike Hammer, Cornelia Jörke, C. Rabenstein, Michael Untch, Katharina Pachmann

    Publicat 2007
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data

    Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data per Oliver Stoß, Andreas H. Scheel, Iris Nagelmeier, Hans‐Ulrich Schildhaus, Thomas Henkel, Giuseppe Viale, Bharat Jasani, Michael Untch, Josef Rüschoff

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Nucleosomes in serum of patients with benign and malignant diseases

    Nucleosomes in serum of patients with benign and malignant diseases per Stefan Holdenrieder, P Stieber, Heinz Bodenm�ller, Martin Busch, Georg Fertig, H. F�rst, Andreas Schalhorn, N. Schmeller, Michael Untch, D. Seidel

    Publicat 2001
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

    Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer per Philipp Kiewe, Stephan Hasmüller, Steffen Kahlert, M Heinrigs, Brigitte Rack, Alexander Marmé, Agnieszka Korfel, Michael Jäger, Horst Lindhofer, Harald Sommer, Eckhard Thiel, Michael Untch

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1

    Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibit... per F. Jänicke, A. Prechtl, Christoph Thomssen, Nadia Harbeck, Christoph Meisner, Michael Untch, Fred C.G.J. Sweep, H. K. Selbmann, H. Graeff, Manfred Schmitt

    Publicat 2001
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Leuprorelin Acetate Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and Fluorouracil As Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: The TABLE Study

    Leuprorelin Acetate Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and Fluorouracil As Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: T... per Peter Schmid, Michael Untch, V. A. Kosse, Grigorij Bondar, Leonid Vassiljev, V I Tarutinov, Ute Lehmann, L. Maubach, Juergen Meurer, D. Wallwiener, Kurt Possinger

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

    HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer per Nadia Harbeck, Matthias W. Beckmann, Achim Rody, Andreas Schneeweiß, Volkmar Müller, Tanja Fehm, Norbert Marschner, Oleg Gluz, Iris Schrader, Georg Heinrich, Michael Untch, Christian Jackisch

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  19. 19
    Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [<sup>18</sup>F]Fluorodeoxyglucose

    Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [<sup>18</sup>F]Fluorodeoxyglucose per Jörg Schwarz-Dose, Michael Untch, Reinhold Tiling, Stefanie Sassen, Sven� Mahner, Steffen Kahlert, Nadia Harbeck, Annette Lebeau, Winfried Brenner, Markus Schwaiger, Fritz Jaenicke, Norbert Avril

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Effect of Once-Weekly Epoetin Beta on Survival in Patients With Metastatic Breast Cancer Receiving Anthracycline- and/or Taxane-Based Chemotherapy: Results of the Breast Cancer—Anemia and the Value of Erythropoietin (BRAVE) Study

    Effect of Once-Weekly Epoetin Beta on Survival in Patients With Metastatic Breast Cancer Receiving Anthracycline- and/or Taxane-Based Chemotherapy: Results of the Breast Cancer—Ane... per Matti Aapro, Robert Leonard, Agustí Barnadas, M. Marangolo, Michael Untch, Nikolaos Malamos, José Mayordomo, Dietmar Reichert, José Luiz Pedrini, Lidia Ukarma, Armin Scherhag, Hans-Ulrich Burger

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: